3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Overweight
1
Osteosarcoma
1
Obesity
1
Neuroblastoma
1
Neoplasm Metastasis
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Infertility
1
Endometrial Neoplasms
1
Advanced Cancer
1
Interventions
Imatinib Mesylate
11
Cyclophosphamide
11
Peripheral Blood Stem Cell Transplantation
9
Cyclosporine
8
fludarabine phosphate
7
Radiotherapy
7
Methotrexate
7
Filgrastim
7
Dasatinib
7
Busulfan
7
Antilymphocyte Serum
7
nilotinib
6
Tacrolimus
6
Mycophenolic Acid
6
Sirolimus
5
Cord Blood Stem Cell Transplantation
5
bosutinib
4
Whole-Body Irradiation
4
Methylprednisolone
4
Melphalan
4
Interferon-alpha
4
ponatinib
3
Alemtuzumab
3
sargramostim
2
Sunitinib
2
Rituximab
2
Moxifloxacin
2
Leucovorin
2
Homoharringtonine
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, Myeloid, Chronic-Phase
×
Tablets
×
Clear all
NCT01827930
2020-12-31
MIM
Institut Bergonié
Phase 3
Terminated
68 enrolled
13 charts